Syngene International launches advanced protein production platform
Syngene International Ltd. (NSE: SYNGENE), a prominent global contract research, development, and manufacturing organization (CRDMO), has announced the launch of a new protein production platform. This innovative platform integrates cell line and transposon-based technology, licensed from the Swiss biotech services company ExcellGene, with Syngene’s own sophisticated clone selection and development processes. This integration promises a notable enhancement in both efficiency and precision of protein production.
Revolutionizing Protein Production
The new platform is set to transform the landscape of preclinical and clinical development by significantly accelerating protein production. This advancement will enable quicker product launches and reduce time to market, crucial for maintaining competitive edge in the biopharmaceutical industry.
Sridevi Khambhampaty, Vice President of Biopharmaceutical Development at Syngene International, highlighted the potential impact of the new platform, stating, “By combining the cell line and transposon-based platform from ExcellGene with our proprietary processes, we are pushing the boundaries in cell line development. This innovative approach will not only accelerate development timelines but also enhance the overall reliability and efficiency of the process, delivering substantial benefits to our clients.”
Strategic Collaboration with ExcellGene
Syngene’s collaboration with ExcellGene brings together leading-edge technologies and expertise. Alex Del Priore, Senior Vice President of Manufacturing Services at Syngene, emphasized the strategic importance of this partnership. “By combining Syngene’s skills and experience with ExcellGene’s best-in-class cell line development technology, we can expedite getting molecules to market for the people and patients who need them,” he stated.
Maria J. and Florian M. Wurm, Cofounders and Managers of ExcellGene, expressed their enthusiasm about the partnership: “We are obviously delighted to partner with and to contribute to Syngene’s process development and manufacturing capabilities. This will leverage our technology and our cells (CHOExpress®) for the benefit of their extensive client base.”
Enhancing Versatility and Productivity
The platform supports a wide range of biomolecules, including monoclonal antibodies, biosimilars, bispecifics, antibody-drug conjugates, and other recombinant proteins. Its versatility is further enhanced by its compatibility with both perfusion and fed-batch manufacturing processes. Syngene’s track record of developing multiple monoclonal antibodies with this new technology underscores its effectiveness and reinforces the company’s ability to provide innovative solutions for its clients.
The introduction of this new protein production platform by Syngene International marks a significant step forward in the biopharmaceutical industry. It not only showcases the company’s commitment to innovation but also its ability to adapt and integrate advanced technologies for enhanced operational efficiency. This move is likely to set new industry standards in protein production, fostering faster development and more efficient manufacturing processes.